Thomas Hazel

Thomas Hazel is a seasoned executive in the field of drug development, currently serving as Vice President of Drug Development at BullFrog AI since December 2021. As an independent consultant since April 2021, Thomas specializes in cell therapy and drug development, assisting clients in enhancing their drug development activities. Previously, Thomas held senior leadership roles including Senior Vice President of Research and Development at Seneca Biopharma, Inc., and Senior Vice President of Research at Neuralstem, Inc. With a robust background in research, including positions at both Innovative Biosensors, Inc. and the National Institutes of Health, Thomas brings extensive expertise in neural stem cell research. Thomas holds a PhD in Genetics from the University of Illinois Chicago and a Bachelor of Arts in Biology from Kalamazoo College.